BriaCell enrolls over 230 patients in phase 3 breast cancer study

May 12, 2026 7:30 AM

BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXL) (TSX: BCT) reported that its Phase 3 Bria-ABC study has enrolled over 230 patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found